ReviewBiomedicines2021
Ovarian Cancer: Biomarkers and Targeted Therapy.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- DeepSynBa: actionable drug combination prediction with complete dose-response profiles.Bioinformatics (Oxford, England) · 2026Article
- Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer.Journal of cancer research and clinical oncology · 2026Article
- Rethinking estrogen receptor β in EAOC: a synergistic modulator in a genomically informed landscape.Journal of ovarian research · 2026Review
- Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- A systematic CRISPR screen reveals an NBL1-mediated Jak/Stat3 crosstalk to promote ovarian cancer metastasis.Genes & diseases · 2026Article
- Integrative transcriptomics and structure-based screening identifiesFrontiers in bioinformatics · 2026Article
- Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer.Scientific reports · 2025Article
- Chrysin-Loaded Micelles Regulate Cell Cycle and Induce Intrinsic and Extrinsic Apoptosis in Ovarian Cancer Cells.Nanomaterials (Basel, Switzerland) · 2025Article
- A Review on Biomarker-Enhanced Machine Learning for Early Diagnosis and Outcome Prediction in Ovarian Cancer Management.Cancer medicine · 2025Review
- GJB2 as a novel prognostic biomarker associated with immune infiltration and cuproptosis in ovarian cancer.Apoptosis : an international journal on programmed cell death · 2025Article
- Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma.Journal of ovarian research · 2025Article
- Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer.Biosensors · 2025Review
- Precision medicine in gynecological cancer (Review).Biomedical reports · 2025Review
- Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing.Cancer medicine · 2025Review
- MARVELD1 as a tumor stem cell marker and therapeutic target in visceral obesity-associated ovarian cancer.American journal of cancer research · 2025Article
- Therapeutic Modulation of the Microbiome in Oncology: Current Trends and Future Directions.Current pharmaceutical biotechnology · 2025Review
- Risk Factors for Ovarian Cancer in South America: A Literature Review.Journal of personalized medicine · 2024Review
- TRIM8 promotes ovarian cancer proliferation and migration by targeting VDAC2 for ubiquitination and degradation.Cancer medicine · 2024Article
- Biomarkers in Ovarian Cancer: Towards Personalized Medicine.Proteomes · 2024Review
- RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.Journal of cellular and molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ovarian cancer is one of the most common causes of death in women as survival is highly dependent on the stage of the disease. Ovarian cancer is typically diagnosed in the late stage due to the fact that in the early phases is mostly asymptomatic. Genomic instability is one of the hallmarks of ovarian cancer. While ovarian cancer is stratified into different clinical subtypes, there still exists extensive genetic and progressive diversity within each subtype. Early detection of the disorder is one of the most important steps that facilitate a favorable prognosis and a good response to medical therapy for the patients. In targeted therapies, individual patients are treated by agents targeting the changes in tumor cells that help them grow, divide and spread. Currently, in gynecological malignancies, potential therapeutic targets include tumor-intrinsic signaling pathways, angiogenesis, homologous-recombination deficiency, hormone receptors, and immunologic factors. Ovarian cancer is usually diagnosed in the final stages, partially due to the absence of an effective screening strategy, although, over the times, numerous biomarkers have been studied and used to assess the status, progression, and efficacy of the drug therapy in this type of disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.